About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 3029 record(s)
Req # A-2022-000095
The COVID-19 vaccination policy for federal employees. Records on the panel that assesses requests from the Public Health Agency of Canada (PHAC) employees for religious exemption.Organization: Health Canada
December 2022
Req # A-2022-000433
The most recent Certified Product Information Document (CPID) for the Mesazaline product from GlaxoSmithKline (GSK).Organization: Health Canada
December 2022
Req # A-2022-000518
All internal records concerning Subway sent after July 1, 2022.Organization: Health Canada
December 2022
Req # A-2022-000525
Any records related to the distribution of rapid tests through the federal government or its partners to the following companies between October 1 2021 and January 1 2022: Camrose Pipe Corporation; Canadian National Steel Corporation; EVRAZ Inc.…Organization: Health Canada
December 2022
Req # A-2022-000816
The most current Canadian Risk Management Plan (RMP) or Canadian Addendum to the RMP and Canadian RMP review report for NEUPOGEN by Amgen Canada Inc., Drug Identification Numbers (DINs) 01968017, 02420104, and 02420112.Organization: Health Canada
December 2022
Req # A-2022-000835
All expense claims and receipts above one hundred dollars from November 20th, 2019 to September 20th, 2022 incurred by the Minister of Health Canada and the Chief of Staff.Organization: Health Canada
December 2022
Req # A-2022-000854
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-09-16 for the medicinal ingredient glatiramer. The…Organization: Health Canada
December 2022
Req # A-2022-000873
Information for all complaints posted against Signatories of the letter (healthcare workers) and involvement of HLS Therapeutics - in relation to health product advertising incidents. All information in relation to incidents received by Health…Organization: Health Canada
December 2022
Req # A-2022-000990
Any cancellation letter(s)/ correspondence which prompted the removal of Degarelix acetate from the Generic Drugs Under Review List dated October 20, 2022.Organization: Health Canada
December 2022
Req # A-2022-001075
All documents related to the negotiation and signing of a contribution agreement regarding the $100 million investment in the Norway House Cree Nation (NHCN) Health Centre of Excellence (HCE) by the Government of Canada announced September 7, 2018,…Organization: Health Canada
December 2022